{"id":"W2135484010","doi":"10.1016/s0140-6736(13)60023-9","title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":354,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Center for Research Resources; U.S. National Library of Medicine; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Child Health and Human Development; Genentech; Dexcom; National Institutes of Health; MacroGenics; Novo Nordisk; Pfizer; Biogen; Juvenile Diabetes Research Foundation United States of America; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amylin Pharmaceuticals; Amgen; Osiris Therapeutics; Halozyme; American Diabetes Association","keywords":"Medicine; Anakinra; Canakinumab; Type 2 diabetes; Immunology; Diabetes mellitus; Interleukin; Clinical trial; Placebo; Internal medicine; Cytokine; Endocrinology; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004462269,0.002316965,0.008010149,0.0006555713,0.0006828315,0.001677674,0.001296929,0.004283469,0.005974182],"category_scores_gemma":[0.004699204,0.001096324,0.004574531,0.0008560393,0.001427522,0.001490317,0.0006163856,0.00340314,0.000702153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001133623,"about_ca_system_score_gemma":0.00118435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001647968,"about_ca_topic_score_gemma":0.003067275,"domain_scores_codex":[0.9982947,0.0008623216,0.0002212174,0.000266504,0.000138267,0.0002170629],"domain_scores_gemma":[0.9974841,0.001167546,0.0005929834,0.0001883323,0.00018704,0.0003799523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9867566,0.0007357872,0.000200419,0.002396732,0.002249367,0.00002569487,0.00003363775,0.00008723022,0.00104088,0.00004316999,0.0003242913,0.006106141],"study_design_scores_gemma":[0.9896981,0.007724075,0.0006835346,0.00009113029,0.00129092,0.00001615297,0.00001136695,0.0000525099,0.00008473905,0.00005811174,0.0002779247,0.00001135062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8312417,0.1453331,0.003025021,0.002619507,0.004294145,0.007878819,0.002068019,0.0003082274,0.003231567],"genre_scores_gemma":[0.9391935,0.04101114,0.003228984,0.002984988,0.001819028,0.006987115,0.00128546,0.00004565244,0.003443967],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008010149,"threshold_uncertainty_score":0.02359903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03385455875871329,"score_gpt":0.303971801463244,"score_spread":0.2701172427045307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}